Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Non-Current Deffered Revenue (2021)

Amylyx Pharmaceuticals (AMLX) has 1 years of Non-Current Deffered Revenue data on record, last reported at $35000.0 in Q4 2021.

  • For Q4 2021, Non-Current Deffered Revenue changed N/A year-over-year to $35000.0; the TTM value through Dec 2021 reached $35000.0, changed N/A, while the annual FY2021 figure was $35000.0, N/A changed from the prior year.
  • Non-Current Deffered Revenue reached $35000.0 in Q4 2021 per AMLX's latest filing.
  • Across five years, Non-Current Deffered Revenue topped out at $35000.0 in Q4 2021 and bottomed at $35000.0 in Q4 2021.